The ability to reprogram somatic into pluripotent cells has revolutionized stem cell research with major implications for almost all fields of modern biology. Reprogramming to a pluripotent state can be achieved by overexpressing the transcription factors Oct4, Sox2, Klf4 and c-Myc (OSKM; refs 1,2). The resulting induced pluripotent stem cells (iPSCs) resemble embryonic stem cells (ESCs), being capable of contributing to chimaeric animals, including the germline 3, 4 . iPS reprogramming of mouse embryo fibroblasts (MEFs) is accompanied by transcriptional and epigenetic remodelling 5, 6 , initiated by the downregulation of the somatic transcriptional program 7, 8 , followed by a mesenchymal-to-epithelial transition 9, 10 (MET). After these changes, pluripotency genes, including Oct4, Nanog and Sox2, become expressed in a small number of cells in the course of about two weeks 7, 8 . In pluripotent cells, ESC-specific super-enhancers 11 (ESC-SEs) bound by Brd4, Med1 and Cdk9, maintain the identity of the cells 12, 13 . Increasing evidence indicates that reprogramming to pluripotency is a complex process, where multiple players synergistically establish new transcriptional networks and remove epigenetic barriers 14 . Among the factors that have been shown to affect the efficiency and kinetics of reprogramming are cell cycle regulators 15, 16 , chromatin remodellers [17] [18] [19] and facilitators of the MET transition 9, 10, 20, 21 . However, a comprehensive understanding of the molecular mechanism of iPS reprogramming is still lacking, in large part because of the low reprogramming efficiency of most somatic cell types 14 . Yamanaka proposed two alternative explanations for this situation: according to the elite-cell model, reprogramming would take place only in a few predisposed cells within a population; and according to the stochastic model most or all cells are competent for reprogramming at low probabilities 22 . We have recently developed an approach that generates the equivalent of 'elite'-type cells, by transiently expressing in pre-B cells (henceforth called B cells) the transcription factor C/EBPα (ref. these Bα cells-unlike control B cells-can be converted into iPSCs at nearly 100% efficiency, also showing that cell reprogramming is basically a deterministic process 23 . Similar efficiencies have been described for genetically modified MEFs and cells treated with specific compound combinations [24] [25] [26] , including fibroblasts and granulocyte/macrophage progenitors 27, 28 (GMPs). Here we have studied the changes induced in B cells by a C/EBPα pulse as well as during the subsequent rapid onset of OSKM-induced reprogramming, by dynamically monitoring transcription-factor-induced changes in transcription, protein expression, enhancer activity and chromatin accessibility.
RESULTS

Changes in culture conditions result in an ultrafast reprogramming system
We have now improved our B cell reprogramming system by culturing the cells under conditions that favour naive pluripotency
A R T I C L E S
were infected with C/EBPαER retrovirus (Fig. 1a) , seeded on MEFs in serum-free medium supplemented with LIF and treated for 18 h with β-oestradiol (E2) to activate C/EBPα, followed by doxycycline to activate OSKM (Fig. 1b) . Two to five per cent of the cells became Oct4-GFP positive within 1 day and 95% after 3 days (Fig. 1c,d) , and Nanog-positive iPSC colonies could already be detected at day 4 ( Fig. 1e) . A comparison of the Oct4-GFP kinetics with cells cultured in medium containing FBS and LIF showed a 4 to 5 day acceleration under the new culture conditions 23 ( Fig. 1d) , which was also confirmed by an independent component analysis of the transcriptome ( Fig. 1f and Supplementary Table 1 ). The resulting iPSCs were found to contribute to chimaera formation after blastocyst injection ( Supplementary Fig. 1A ).
RNA-seq experiments showed the activation of Oct4 within 1 day after OSKM induction and of Nanog within 2 days, correlating with the genes' decoration by the activating mark H3K27ac (Fig. 1g ). The 12,781 genes whose expression changed >2-fold at any given time point were subdivided into nine groups by C-means clustering, and analysed for Gene Ontology (GO) annotations ( Fig. 1h and Supplementary Fig. 1B ,C). Genes in clusters I and II became downregulated following the C/EBPα pulse/OSKM expression and were enriched for the GO terms 'B cell activation' and 'immune response' . In contrast, genes in cluster III became transiently upregulated and were enriched for 'epigenetic regulation of gene expression' and 'chromatin organization' , whereas cluster V was enriched for 'mesenchymal-epithelial transition (MET)' and 'cell adhesion' . Finally, genes in clusters VIII and IX were upregulated by OSKM and enriched for 'stem cell maintenance' and 'blastocyst formation' , containing the pluripotency genes Nanog and Klf4.
Pluripotency genes were activated in three waves, initiated by Oct4, Lin28a, Zfp296, Gdf3 and Tdh at day 1, followed by Nanog at day 2, and by Sall4, Sox2, Esrrb and Zfp42 (Rex1) at day 4 ( Supplementary  Fig. 1D ). Changes in expression of pluripotency genes were confirmed at the protein level ( Supplementary Fig. 1E ).
In the following, we will use this ultrafast reprogramming system to investigate changes at the protein and chromatin levels, both after the initial expression of C/EBPα and following OSKM induction.
The C/EBPα pulse elevates the levels of multiple proteins, without concomitant transcriptional changes To analyse proteome dynamics during reprogramming, we performed shotgun proteomics by label-free quantification of samples from the four reprogramming time points and ESCs. We detected 7,497 proteins that included 520 transcription factors, 295 kinases, 141 phosphatases and 96 isomerases (Supplementary Fig. 2A) , showing an excellent correlation between duplicates ( Supplementary Fig. 2B ). C-means clustering of the proteins that changed >2-fold at any given time point resulted in ten groups ( Fig. 2a and Supplementary  Fig. 2C ). Downregulated proteins (clusters a,b) were highly enriched for the GO terms 'B cell immunity' and 'immune system' (Fig. 2b) . The early upregulated proteins were found to be associated with the terms 'RNA splicing' and 'protein degradation' (Supplementary  Table 2 ). In contrast, late upregulated proteins (clusters i,j) were enriched for 'stem cell maintenance' and 'stem cell development' and contained Oct4 and Sox2. Surprisingly, 439 out of 538 proteins elevated in Bα cells (clusters g,h) were not regulated at the RNA level (Fig. 2c) . These belonged to the categories 'chromatin remodelling' and 'histone modifications' and included the epigenetic factors Lsd1, Hdac1, Brd4 and Med1. The observed accumulation at the protein level of the histone demethylase Lsd1 (Kdm1A) and the histone deacetylase Hdac1 (Fig. 3a) could also be confirmed by western blot (Supplementary Fig. 3A) .
A protein complex containing Lsd1, Hdac1 and C/EBPα mediates B cell gene silencing Lsd1 is known to demethylate H3K4me1/2 (ref. 30) and to be part of a complex that includes the histone deacetylase Hdac1 (ref. 31 ). Hdac1 in turn has been described to interact with C/EBPα (ref. 32) . We therefore investigated whether C/EBPα can interact with both Lsd1 and Hdac1 and whether the complex is required to silence B cell gene expression ( Supplementary Fig. 3B ) during reprogramming. Gel-filtration chromatography showed that C/EBPα, Lsd1 and Hdac1 co-elute in a high-molecular-weight complex ( Supplementary  Fig. 3D ). Furthermore, C/EBPα immunoprecipitation followed by mass spectrometry revealed an interaction with Lsd1 and Hdac1 ( Fig. 3b and Supplementary Fig. 3E ), a finding confirmed by western blot ( Supplementary Fig. 3F ). Our proteomic analyses also showed an interaction of C/EBPα with Wdr5 and other members of the MLL complex, as recently reported 33 . Finally, an antibody against Lsd1 co-immunoprecipitated Hdac1 and C/EBPα (Fig. 3c) , but not the control proteins Pcna and Parp1 ( Supplementary Fig. 3G ), further supporting the proposed association between C/EBPα, Lsd1 and Hdac1.
As the Lsd1/Hdac1 complex has been shown to regulate the inactivation of super-enhancers 31 (SEs), we tested the effect of C/EBPα on B cell SEs (B-SEs), examining 514 regions with high H3K27ac levels 11, 34 . This revealed a marked reduction in B-SE activity, as seen by the loss of H3K27ac and Brd4 ( Fig. 3d and Supplementary Fig. 3H ). We also found a significant decrease in the activation-associated marker H3K4me2 at regulatory elements of the B cell genes Ebf1, Fox1, Gfi1b and Ikzf3 (ref. 35) , as well as of the lymphoid Rag1 and Ciita genes (Fig. 3e) .
To test whether Lsd1 is required for the C/EBPα-mediated B cell silencing ( Supplementary Fig. 3B ) and decrease in B-SE activity, we tested the effect of S2101, a compound that specifically blocks the enzymatic activity of Lsd1 (ref. 36) . We found that it indeed prevented the C/EBPα-induced decommissioning of B cell enhancers (Fig. 3e ) and, at least in part, B cell silencing (Fig. 3f) , as did Hdac1 inhibition ( Supplementary Fig. 3I ). Lsd1 was also found to be required for the fast reprogramming of B cells into iPS cells as S2101 treatment impaired Oct4-GFP upregulation and markedly reduced the number of iPS colonies (Fig. 3g-i) . This was not due to an adverse effect of Lsd1 inhibition on B cell viability ( Supplementary Fig. 4A ) or proliferative capacity ( Supplementary Fig. 4B ). Knockdown experiments confirmed these observations, yielding reduced numbers of iPS colonies ( Fig. 3j and Supplementary Fig. 4C-E) . Interestingly, OSKM-induced reprogramming of B cells not exposed to C/EBPα was not inhibited by S2101 ( Supplementary Fig. 4F ), indicating that Lsd1 acts downstream of C/EBPα.
These results show that inhibition of Lsd1 and Hdac1 impairs enhancer decommissioning and B cell gene silencing in Bα cells. C/EBPα post-transcriptionally increases Brd4, Med1 and Cdk9 protein levels and Brd4 is required for reprogramming The C/EBPα pulse also caused a marked and coordinated posttranscriptional increase of Brd4, Med1 and Cdk9 as detected by mass spectrometry and western blot ( Fig. 4a and Supplementary Fig. 3A,C) . This is intriguing as recent studies have shown that a complex containing Brd4, Med1 and Cdk9 is required for the self-renewal capacity and pluripotency of ESCs (ref. 12 ) and for reprogramming of MEFs (ref. 13) , and that Brd4 inhibition results in the complex's disruption 12 . As Brd4 is also required for SE activity 37 , we analysed the changes of H3K27ac decoration at ESC-SEs during reprogramming. Notably, some ESC-SEs became already activated in Bα cells (Fig. 4b) , including the Lefty and Rarg enhancers, and 19/32 showed increased Brd4 binding. This finding raised the possibility that C/EBPα recruits Brd4 to acetylated histone tail residues 38 . To test this hypothesis, we performed ChIP-seq experiments with B cells and Bα cells and found that C/EBPα and Brd4 co-occupy approximately 25% of the newly bound sites, including ESC-SEs of Id1, Iqgap1, Rarg and Egln3 genes (Fig. 4c,d and Supplementary Fig. 4G ). Co-immunoprecipitations further confirmed that the two proteins form a complex (Fig. 4e) , as was also recently described 38 .
Next we tested whether Brd4 inhibition impairs iPS reprogramming by using the compound JQ1, known to effectively inhibit the function of bromodomain and extraterminal domain (BET) family proteins, including Brd4 (ref. 39) . JQ1 was either administered only during the pulse or during a two-day doxycycline treatment. Cells were monitored for the expression of Oct4-GFP by fluorescenceactivated cell sorting (FACS) or of key pluripotency genes. Strikingly, JQ1 treatment completely inhibited Oct4-GFP activation (Fig. 4f) and significantly reduced the upregulation of Oct4, Lin28a, Zfp296, Lefty1 and Cdh1 when administered during both the C/EBPα pulse and OSKM activation (Fig. 4g) . Finally, we observed a threefold reduction of iPSC colonies when the drug was administered during the C/EBPα pulse and a tenfold impairment when provided together with doxycycline ( Fig. 4h and Supplementary Fig. 4H ), a finding confirmed with an short hairpin RNA (shRNA) against Brd4 ( Fig. 4i and Supplementary  Fig. 4C-E) . Of note, the concentration of JQ1 used did not severely affect B cell survival or proliferation ( Supplementary Fig. 4A,B) .
We conclude that C/EBPα induces a post-transcriptional accumulation of the Brd4-Med1-Cdk9 complex and re-localizes Brd4 to ES-SEs. Our data also show that Brd4 is strictly required for iPS cell formation from B cells. The data represent the average from two biologically independent samples. (b) C/EBPα immunoprecipitation mass-spectrometry data (based on three experiments using a specific antibody and three using IgG control serum). Statistical significance was determined using a two-tailed unpaired Student's t-test (n = 3 biologically independent samples). . Statistical significance was determined using a two-tailed unpaired Student's t-test ( * P < 0.05, * * P < 0.01, * * * P < 0.001). (h) Oct4-GFP + iPSC colonies at day 12 of reprogramming, after treatment of B cells with JQ1 during either C/EBPα or OSKM induction. Error bars indicate s.d. (n = 3 biologically independent samples). Statistical significance was determined using a two-tailed unpaired Student's t-test ( * * * P < 0.001). (i) Nanog + iPSC colony counts after reprogramming of B cells with a knockdown for Brd4. Error bars indicate s.d. (n = 3 biologically independent samples). Statistical significance was determined using a two-tailed unpaired Student's t-test ( * * * P < 0.001).
C/EBPα induces chromatin accessibility at selected pluripotency loci To study changes in chromatin accessibility, we used ATAC-seq 40 to identify accessible chromatin regions and reveal potential regulatory elements bound by transcription factors. After calling discrete ATAC peaks, we identified 6,319 regions with distinct dynamics during the time course, which were divided by C-means clustering into four groups (Fig. 5a ). Cluster I contained 525 regions with ATAC peaks formed de novo after the C/EBPα pulse and that reach maximum accessibility in ESCs. Their association with GO categories 'developmental process' and 'embryo development' (Fig. 5a and Supplementary Fig. 5A ) suggests that they mark sites associated with pluripotency. In contrast, most ATAC peaks induced by the C/EBPα pulse, represented in clusters II, III and IV, diminished in day 2 cells and were poorly represented in ESCs. GO analyses of genes associated with these regions revealed an enrichment for myeloid genes ( Supplementary Fig. 5A ) as exemplified by Id1 and Ifitm6, genes that are upregulated by C/EBPα ( Supplementary Fig. 5B ). We then investigated the presence of transcription-factor-binding motifs within ATAC-seq peaks. As predicted, cluster I regions were strongly enriched for motifs associated with pluripotency transcription factors such as Klf4, Oct4, Sox2 and Essrb. In contrast, newly accessible regions in clusters II, III and IV were enriched for potential binding sites of the myeloid transcription factors PU.1 (Ets), C/EBPα, Irf8 and Runx1 (Fig. 5b , and Supplementary Fig. 5C ).
C/EBPα directly regulates Klf4 expression and together they increase chromatin accessibility
Klf motif enrichment in ATAC cluster I suggested that Klf4 might already be expressed in Bα cells. We found that it was indeed transcriptionally upregulated >2-fold by C/EBPα (Fig. 5c,d ), a finding confirmed by western blot ( Supplementary Fig. 3A) . Remarkably, C/EBPα binds to two regions upstream of Klf4 (−90 kb and −280 kb) that are also occupied by Brd4 and PU.1 and were enriched for H3K27ac, suggesting that these sites represent active enhancers (Fig. 5e and Supplementary Fig. 5D ). Circularized chromosome conformation capture (4C-Seq) experiments support this interpretation, revealing that the Klf4 promoter interacts with these two regions in Bα cells but not in B cells (Fig. 5e and Supplementary Fig. 5D ). Interestingly, in ESCs these enhancers showed no activity and no looping with the Klf4 promoter, which interacted instead with a +50 kb enhancer (Fig. 5e ). In addition, co-transfection of the −90 kb enhancer linked to a luciferase reporter with C/EBPα enhanced reporter activity, whereas both C/EBPα and PU.1 were necessary to activate the −280 kb enhancer (Fig. 5f ). Their differential responsiveness to the two transcription factors can be explained by the observation that in B cells the −280 kb, but not the −90 kb enhancer, is primed by endogenous PU.1 ( Supplementary Fig. 5D ), a transcription factor known to synergize with C/EBPα (ref. 41) .
To explore the possibility of interplay between C/EBPα and Klf4, we compared the binding sites of the two factors and analysed their enrichment at the ATAC peaks within the four clusters. Supporting our motif analyses, Klf4 binding showed the strongest enrichment at cluster I sites, decreasing progressively towards cluster IV, whereas C/EBPα binding showed the reverse trend (Fig. 5g) . In ESCs, cluster I sites were specifically enriched for Brd4 and Klf4 binding, highlighting the known interaction between the two factors 13 ( Supplementary  Fig. 5E ). Our data also showed that approximately 5% of regions bound by C/EBPα in Bα cells are bound by Klf4 in pluripotent cells ( Supplementary Fig. 5F ), raising the possibility that here C/EBPα acts as a pioneer factor for subsequent Klf4 binding. Analysis of MNaseseq and C/EBPα ChIP-seq data obtained after C/EBPα activation 41 , generated in an inducible pre-B cell line, support this hypothesis ( Supplementary Fig. 5G ). A pioneering role of C/EBPα is also suggested for the pluripotency-associated genes Rarg and Lefty1/2. C/EBPα binds to the enhancers of these genes in Bα cells, which then become activated, as seen by their decoration with H3K27ac and Brd4 (Fig. 5h) . Following OSKM induction, these enhancers become subsequently bound by Klf4 and further activated. Moreover, both regions are bound by Oct4, Nanog, Sox2, Klf4 and Brd4 in ESCs and are also enriched for H3K27ac, confirming that they correspond to active pluripotency enhancers ( Supplementary Fig. 6A ). Consistent with this interpretation, Rarg and Lefty1 become upregulated during reprogramming ( Supplementary Fig. 6B ).
In conclusion, C/EBPα creates a large number of newly accessible chromatin regions in B cells and it upregulates Klf4 by binding to two haematopoietic enhancers. C/EBPα and Klf4 subsequently facilitate accessibility to other pluripotency-associated transcription factors, as exemplified for the Lefty and Rarg enhancers.
C/EBPα and Klf4 link the elite cell state of Bα cells to that of granulocyte/macrophage progenitors
GMPs are the cells within the haematopoietic system most susceptible to OSKM-induced reprogramming, with 25% to >90% % of single seeded cells converting into iPSCs (refs 25-28; summarized in Fig. 6a) , thus representing an 'elite' or 'privileged' cell state. C/EBPα-deficient mice lack GMPs (ref. 42) , showing that their formation strictly requires C/EBPα. To compare Bα cells and GMPs, we performed expression microarray and RNA-seq experiments. Cebpa was expressed >100-fold higher in GMPs than in B cells and ESCs (Fig. 6b) , whereas Klf4 was expressed about fivefold higher in Bα cells and GMPs compared with B cells (Fig. 6b) . Moreover, C/EBPα binds to the −90 and −280 kb Klf4 enhancers in GMPs (ref. 43 ; Fig. 6c ), raising the possibility that C/EBPα and Klf4 co-regulate a substantial proportion of genes in GMPs and Bα cells. Indeed, almost 30% of the genes expressed in GMPs-but not B cells-were also found to be expressed in Bα cells ( Supplementary Fig. 6C ). Furthermore, a canonical variate analysis showed that Bα cells are most similar to GMPs when compared with all other haematopoietic populations ( Supplementary Fig. 6D ). We then performed ATAC-seq in GMPs to test whether chromatin accessible regions in Bα cells are also accessible in these cells. Strikingly, of 525 newly accessible regions in Bα cells, 357 overlapped with ATAC peaks in GMPs (Fig. 6d and Supplementary Fig. 6E,F) , which were not detectable in MEFs (ref. 44 ; Supplementary Fig. 6F ). This is exemplified by the pluripotency genes Lefty and Rarg and the myeloid genes Tet2, Ifitm6 and Id1 (Supplementary Fig. 6G ). Furthermore, the intersection between C/EBPα and ATAC-seq peaks in Bα cells shows that C/EBPα binding exhibits a similar enrichment in GMPs ( Supplementary Fig. 6H and Fig. 5g ).
Rapidly cycling GMPs express elevated levels of Klf4 and Tet2
It was recently reported that a rapidly cycling GMP sub-fraction can be reprogrammed into iPSCs at a >3-fold higher efficiency than the slowly cycling sub-fraction 28 . We therefore determined whether the elite-cell-associated factors Klf4 and Tet2, which have been shown to enhance the reprogramming efficiency of B cells and MEFs (refs 23,45) , are differentially expressed in the two cell fractions. For this purpose, GMPs from reprogrammable mice were labelled with CFSE and separated into a CSFE-high fraction (slow-cycling cells) and a CSFE-low fraction (fast-cycling cells; Supplementary Fig. 7A ). The fast-cycling GMPs expressed twofold more Klf4 and 1.5-fold more Tet2 than the slow-cycling cells, a finding confirmed by RNA-seq and quantitative real-time PCR (qRT-PCR) for Klf4 (Fig. 6e,f and Supplementary Fig. 7B ) whereas the slow-dividing cells expressed higher levels of the cell cycle inhibitor Cdkn1a (p21; Fig. 6e ). In contrast, the two cell fractions did not differ in their expression of Cebpa and Cebpb nor of Lsd1, Hdac1, Brd4, Med1 and Cdk9 ( Supplementary Fig. 7C ), in line with the observation that C/EBPα regulates these genes only at the protein level. Finally, we examined the role of Tet2 in the reprogramming to iPSCs of both B cells and GMPs. After Tet2 knockdown, we observed a significant decrease in the number of iPSC colonies for both cell types (Fig. 6g,h and Supplementary Fig. 7D ).
DISCUSSION
Our results describe molecular mechanisms by which a pulse of the transcription factor C/EBPα converts B cells into elite cells for reprogramming into iPSCs. C/EBPα initiates the reprogramming cascade by concomitantly boosting the levels of protein complexes required for silencing the B cell program and for establishing the pluripotency program. C/EBPα also controls Klf4 expression by binding to two haematopoietic specific enhancers, allowing the two factors to induce chromatin accessibility at regions that become fully accessible in pluripotent cells (Fig. 7a,b) .
Our most surprising observation was that C/EBPα posttranscriptionally increases the levels of hundreds of proteins, including key chromatin-modifying factors. The finding that C/EBPα interacts with Lsd1 (Fig. 3b,c) , Hdac1 (Fig. 3b,c and ref. 32 ) and Brd4 (Fig. 4e) raises the possibility that it could increase protein stability Statistical significance was determined using a two-tailed unpaired Student's t-test ( * * * P < 0.001, * * P < 0.01). (h) Nanog + iPSC colony counts after reprogramming of GMPs with a knockdown of Tet2. Error bars indicate s.d. (n = 3 biological independent experiments). Statistical significance was determined using a two-tailed unpaired Student's t-test ( * * P < 0.01).
by preventing their ubiquitin-mediated degradation. In support of this possibility, proteasome inhibition has indeed been shown to increase the levels of Lsd1 and Hdac1 (refs 46,47) . The finding that Lsd1 is required for the inactivation of B-SEs and the silencing of the B cell program suggests that it has a similar role as in ESCs, where it is responsible for the decommissioning of ESC-SEs during differentiation 31 . The observation that the Brd4 inhibitor JQ1 blocks reprogramming supports recent reports demonstrating that the Brd4-Med1-Cdk9 protein complex is required for reprogramming of MEFs (ref. 13 ) and for the maintenance of pluripotency of ESCs (ref. 12). That JQ1 also impaired reprogramming when used to treat B cells during the C/EBPα pulse was unexpected, but could be explained by the ability of C/EBPα to recruit Brd4 to ESC-SEs required for activation of pluripotency genes. Together, these results suggest that Brd4 is generally required for cell fate conversions and Lsd1 acts in a more tissue-restricted manner. In line with this interpretation, we found that JQ1 impairs the TFIID-enhanced reprogramming of MEFs into iPSCs (ref. 48) , whereas S2101 exhibited a slight acceleration (Supplementary Fig. 7E ).
As summarized in Fig. 7b , several lines of evidence help to explain why GMPs, like Bα cells, behave as elite cells for reprogramming: (i) GMPs express high levels of C/EBPα and strictly require the gene for their formation 42 ; (ii) Klf4 is more highly expressed in GMPs than in B cells. In addition, the rapidly cycling GMP subpopulation with higher reprogramming efficiency express elevated levels of Klf4 (Fig. 6e,f) ; (iii) Tet2 is upregulated by C/EBPα, highly expressed in GMPs and required for the efficient reprogramming of both cell types 23 ( Fig. 6g,h) ; (iv) GMPs specifically express a large set of differentiation-related genes shared with Bα cells 49 ( Supplementary Fig. 6C,D) ; (v) GMPs share a substantial cohort of accessible chromatin regions (ATAC-seq cluster I) present in ESCs but not in B cells or MEFs.
Our data indicate that the interplay between C/EBPα and Klf4 induces chromatin accessibility to pluripotency factors as exemplified for the Rarg and Lefty enhancers where C/EBPα binds first followed by Klf4 (Fig. 5h) . As described here and elsewhere 41 , C/EBPα can act as a pioneer factor and Klf4 has also been shown to bind to closed chromatin 50 . However, it is possible that the predominant effect of C/EBPα is to activate Klf4, which subsequently binds to and activates other pluripotency genes (Fig. 5h) .
Myeloid progenitors, including GMPs, also play an important role in blood cell malignancies because they have been shown to be key target cells in a mouse model for MLL-AF9-induced acute myeloid leukaemia 51 (AML). Strikingly, their oncogenic transformation strictly depends on the C/EBPα-driven differentiation to the GMP stage and/or on the transcriptional activity of C/EBPα (ref. 52) , compatible with the notion that C/EBPα is responsible for chromatin remodelling events necessary for leukaemia [51] [52] [53] . It will now be interesting to determine whether the increase in the levels of chromatinmodifying factors described here also plays a role in AML formation, especially in view of the observation that human AML cells typically exhibit high levels of Lsd1 activity 54 . Our recent demonstration that C/EBPα can also poise human B cells for enhanced OSKMinduced reprogramming 55 underscores the factor's capacity to act across species.
Our findings have provided insights into the mechanism by which C/EBPα creates an elite cell state in B cells and the earliest events in reprogramming to iPSCs. It will now be interesting to determine whether upregulation of chromatin-related factors is a more general feature of somatic cell reprogramming, and whether this is also important for the GMP formation and their predisposition to malignancy.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3326
Mice. We used a cross between 'reprogrammable mice' containing a doxycyclineinducible OSKM cassette and tetracycline transactivator 56 , and the Oct4-GFP reporter 57 , as previously described 23 (Fig. 1a) . B cell isolation was routinely performed from 8-to 16-week-old male and female mice.
Mice were housed in standard cages under 12 h light-dark cycles and fed ad libitum with a standard chow diet. All experiments were approved by the Ethics Committee of the Barcelona Biomedical Research Park (PRBB) and performed according to Spanish and European legislation.
Cell cultures. ESCs (E14TG2) were cultured on gelatinized plates in N2B27 media (50% DMEM-F12, 50% Neurobasal medium, N2 (100×), B27 (50×)) supplemented with small-molecule inhibitors PD (1 µM, PD0325901) and CHIR (3 µM, CHIR99021), as well as LIF (10 ng ml −1 ). CD19 + pre-B cells were obtained from bone marrow of reprogrammable mice with monoclonal antibody against CD19 (concentration of 0.2 µg per 10 6 cells; clone 1D3, BD Pharmingen, Cat. no. 553784) using MACS sorting (Miltenyi Biotech). Cell purity was confirmed by FACS using an LSR2 machine (BD) (>98%). After isolation, B cells were grown in RPMI medium supplemented with 10% FBS and 10 ng ml −1 IL-7 (Peprotech), 100× L-glutamine, 100× penicillin/streptomycin, 100× nonessential amino acids, 1,000× β-mercaptoethanol (Life Technologies). Lin − c-Kit + Sca-1 − CD16 + /CD32 + CD34 + GMP cells were isolated by FACS sorting using a BD INFLUX sorting machine and cultured in STEMSPAN medium (Stemcell Technologies) supplemented with 100 ng ml −1 SCF, 50 ng ml −1 IL3, 50 ng ml −1 Flt3L and 50 ng ml Reprogramming experiments. Pre-B cells were isolated from the bone marrow of reprogrammable mice crossed with Oct4-GFP mice, infected with C/EBPαER-hCD4 retrovirus, plated at 500 cells cm −2 in gelatinized plates (12 wells) on irradiated MEF feeders in RPMI medium. To activate C/EBPα, cultures were treated for 18 h with 100 nM β-oestradiol (E2), resulting in Bα cells.
After E2 washout, the cultures were switched to serum-free N2B27 medium supplemented with IL-4 10 ng ml −1 , IL-7 10 ng ml −1 and IL-15 2 ng ml −1 . To activate OSKM, the cultures were treated with 2 µg ml −1 of doxycycline. From day 2, onwards we supplemented the N2B27 medium with 20% KSR (Life Technologies), 3 µM CHIR99021 and 1 µM PD0325901.
OSKM Oct4-GFP MEFs were seeded in gelatinized plates and induced with 2 µg ml −1 of doxycycline in ES medium.
A step-by-step protocol describing the reprogramming procedure can be found at Nature Protocol Exchange 58 . All cell lines have been routinely tested for mycoplasma contamination.
Stable cell lines.
The PlatE retroviral packaging cell line was obtained from Cell Biolabs (Cat. no. RV-101). The C10 pre-B cell line stably expressing C/EBPαER-GFP has been described previously 59 .
Immunofluorescence. For Nanog staining, the cells were fixed with 4% paraformaldehyde, blocked and incubated with the primary antibody (1:500; Calbiochem, SC100) overnight at 4 • C. They were then stained with secondary anti-rabbit antibodies (1:1,000; Alexa Fluor 547, Life Technologies) at room temperature for one hour. Nuclear staining was performed with DAPI (Invitrogen).
RNA extraction.
To remove the feeders, cells were trypsinized and preplated for 30 min before RNA isolation with the miRNeasy mini kit (Qiagen). RNA was eluted from the columns using RNase-free water and quantified by Nanodrop. cDNA was produced with the High Capacity RNA-to-cDNA kit (Applied Biosystems).
FACS analyses. Oct4-GFP expression was analysed with an LSR II FACS (BD Biosciences) using Diva v6.1.2 (BD Biosciences) and FlowJo software v10 (TreeStar).
Isolation of fast-and slow-cycling cells. CFSE (Life Technologies) was used to subdivide GMPs into fast-and slow-cycling cell populations. 3 × 10 5 cells were resuspended in 1 ml PBS with 0.2 µM of CSFE for 5 min and then rinsed twice with four volumes of PBS. After 24 h, cells were sorted on the basis of FITC brightness as indicated in Supplementary Fig. 8A .
Gene expression arrays. RNA samples with a RIN > 9 were subjected to transcriptional analyses using Agilent expression arrays. For hybridization, 500 ng of total RNAs were labelled using Agilent's QuickAmp labelling kit and hybridized to Agilent 8X60K expression arrays.
qRT-PCR analyses. qRT-PCR reactions were set up in triplicate with the SYBR Green QPCR Master Mix (Applied Biosystems) and primers as listed in Supplementary  Table 3 BrdU staining. To check cell proliferation, BrdU was added to the culture medium at a concentration of 10 µM for 6 h. Staining was performed using the BrdU APC Flow Kit from BD Pharmingen.
Cell viability. Cell viability was assessed using the Pacific Blue Annexin V/SYTOX AADvanced Apoptosis Kit for flow cytometry from Thermo Fisher Scientific.
Luciferase assay. The −90 kb and −280 kb enhancers of Klf4 were amplified by qPCR using the following primers: −90 kb forward 5 -GCCCTCGAGCGGGTCTGGCCT TCAGTGATA-3 and reverse 5 -GCCATGCATCCGGACTCCCTTTTGCTAGTG -3 ; −280 kb forward 5 -GCCCTCGAGCTGGTATATGCACACATGCAC-3 and reverse 5 -GCCCTGCAGCTCTCCCTGCATTGGCTTAGT-3 .
The PCR fragments were digested using either XhoI and PstI or XhoI and NsiI and cloned in the CSI-LUC2-minP vector in the XhoI and PstI sites.
Twelve-well plates with 293T cells were transfected with 0.1 µg of a β-galactosidase control plasmid, 0.5 µg of the respective enhancer plasmid or the empty vector and 0.5 µg of C/EBPα, or 0.5 µg of C/EBPα and PU.1 plasmids or 0.5 µg of GFP plasmid using the TransIT transfection reagent (Mirus). Luciferase and β-galactosidase activities were measured using the Luciferase Assay System (Promega) and the β-Galactosidase Enzyme Assay System (Promega) following the manufacturer's protocol. All experiments were carried out in triplicates and normalized to β-galactosidase activity to account for differences in transfection efficiencies.
Vectors and virus production and infection. The retroviral vectors LMN-
Ctrl-shRNA-PGK-GFP and LMN-Lsd1-shRNA-PGK-GFP were purchased from Transomic Technologies. The retroviral vector containing the Brd4 shRNA (no. 552) has been described previously 60 . The pMX vectors of TAF4, TAF5, TAF6 and TBP (ref. 48) were obtained from Addgene. The retroviral vector Tet2-shRNA-PGK-GFP has been described previously 61 . The C/EBPαER-hCD4 retroviral vector has been used before 62 . Viral production and B cell infection were performed as described previously 62 . For the infection of GMPs, freshly sorted cells were infected by centrifugation for 90 min on Retronectin (Clontech)-coated plates.
4C. 4C-seq was performed as described previously 63 . Briefly, 0.5-1.0 million crosslinked nuclei were digested with Csp6I followed by ligation under dilute conditions. After decrosslinking and DNA purification, samples were digested overnight with DpnII and once more ligated under dilute conditions. Columnpurified DNA was directly used as input for inverse PCR using primers (Supplementary Table 3 ) with Illumina adapter sequences as overhangs. Several PCR reactions were pooled, purified and sequenced on an Illumina HiSeq 2500.
DOI: 10.1038/ncb3326 M E T H O D S
20 min, followed by addition of 1% formaldehyde, 10 min, both steps with rotation at room temperature. Chromatin was sheared to 200-bp fragments using a Bioruptor sonicator and 0.5 ml siliconized tubes. H3K27ac-carrying histones were precipitated using four low-salt RIPA-buffer washes and protein A Sepharose beads, C/EBPα and Brd4 using six low-salt RIPA-buffer washes and protein G and protein A beads respectively, and Klf4 with two low-and two high-salt RIPA washes and protein G beads. See below for the references of the antibodies used.
Protein fractionation. Gel-filtration experiments were performed in the Biomolecular Screening & Protein Technologies Facility using a Superose 6 10/300 GL column (GE Healthcare). For analysis of endogenous Lsd1-Hdac1-C/EBPα complex, Bα cells were lysed in RIPA buffer, and 1 mg of cleared lysate was loaded onto a single Superose 6 10/300 GL column, calibrated using a mixture of molecular mass marker proteins (MWGF1000, Sigma-Aldrich). A 300 µl portion of lysate was loaded onto the column and collected into 250 µl fractions; fractions were processed for western blot analysis.
Co-immunoprecipitation experiments and western blots.
Owing to the large number of cells required, the immunoprecipitation experiments were performed in an inducible, C/EBPαER-containing C10 pre-B cell line 59 ; the western blots were performed with primary cells. Cell lysates were prepared using NET-2 buffer (200 mM NaCl, 50 mM Tris pH 7,5, 0.1% Triton and 1× protease inhibitors) for 20 min at 4 • C and centrifugated for 10 min at 16,000g to remove cellular debris. Supernatants were used for protein detection by western blot or for co-immunoprecipitation. For the latter 19/20 of the extract was pre-cleared with magnetic beads (Dynabeads, Invitrogen) by rotating for 2 h on a wheel at 4 • C. Onetwentieth of the lysates was kept as the input. Separately, to crosslink the antibodies to beads, 50 µl of beads were incubated with 3 µg of antibody or IgG for 2 h at room temperature on a wheel and then washed once with PBS and twice with 0.2 M triethanolamine pH 8.2. The suspension was then incubated for 20 min at room temperature with 20 mM dimethyl pimelimidate, the reaction stopped with two 5 min washes with 50 mM Tris pH 8 followed by three washes with PBS and the beads incubated with 0.1 M citric acid pH 3 for 2 min to remove non-crosslinked antibodies followed by two washes with lysis buffer. Finally, the crosslinked antibodies were incubated with the pre-cleared protein extracts overnight at 4 • C on a wheel and the beads selected with a magnet, 1/20th of the supernatant kept as the unbound control fraction and the beads washed six times with lysis buffer. To elute, the beads were resuspended in 1× Laemmli buffer (without βME) and heated for 20 min at 60 • C. Magnetic beads were then separated with a magnet, the supernatant complemented with 5% βME and boiled before loading in an SDS-PAGE acrylamide gel to analyse bound proteins by western blotting. As controls, one lane was loaded with the original input, another lane with the unbound fraction and a third lane with beads coupled to either mouse or rabbit IgG. Finally, after transferring the proteins to a membrane, the blot was blocked with 5% milk in TBS-Tween, probed with an antibody to the homologous protein, and after developing stripped and probed with an antibody against the antigen tested for interaction. C/EBPα immunoprecipitation for mass spectrometry. For affinity purification experiments of C/EBPα, we used our inducible, C/EBPαER-containing C10 pre-B cell line 59 . Immunoprecipitations were performed using three separate samples with antibody (Santa Cruz, SC-61) and three samples with IgG essentially as above but without pre-clearing and without crosslinking the antibodies to the beads. After overnight incubation with extracts, beads were washed three times with NET-1.5 buffer (150 mM NaCl, 50 mM Tris pH 7.5, 0.1% Triton) and twice with TBS. Precipitated proteins were eluted with elution buffer (6 M urea, 2 M thiourea, 10 mM Hepes pH 8.0) containing 2 mM dithiothreitol for 30 min at room temperature, followed by a second elution with elution buffer. Both elutes were combined, alkylated with 5 mM CAA, diluted 5 times with 50 mM ammonium bicarbonate and digested with 1 µg trypsin overnight at room temperature. The resulting peptide mixtures were acidified with 1% TFA, desalted with StageTips containing three layers of C18 material and analysed by mass spectrometry as described below.
Antibodies for ChIPs, western blots and immunoprecipitations. The antibodies used in this study were H3K4me2 (2 µg for 25 µg of chromatin) (Abcam, ab7766), Lsd1 (1:1,000) (Kdm1a, Abcam, ab17721), Brd4 (ChIP: 2.5 µg ml −1 ) (Bethyl Laboratories, A301-985A); (western blot: 1:1,000) (Abcam, ab128874), H3K27ac (1 µg ml −1 ) (Abcam, ab4729), Klf4 (1:200) (R&D, AF3158), Hdac1 (1:2,000) (Abcam, ab7028), C/EBPα (western blot: 1:300) (Santa Cruz, SC-61); (ChIP: 0.2 µg ml −1 ) (Santa Cruz, SC-61), PU.1 (0.5 µg ml −1 ) (Santa Cruz, SC-352X), ERα antibody (1:500) (Santa Cruz, SC-543), H3 (1:2,000) (Abcam, ab1791), Parp (1:1,000) (no. 9542, Cell Signaling), β-tubulin (1:5,000) (Sigma, T7816), GAPDH (1:1,000) (Santa Cruz, SC-32233), PCNA (1:400) (Santa Cruz, SC-56 (PC10)), Cdk9 (1:1,000) (Cell Signaling, rabbit mAb no. 2316), Oct4 (1:200) (Santa Cruz, SC-8628), Gdf3 (1.5 µg ml −1 ) (R&D, AF958), Lin28a (1:1,000) (Cell Signaling, no. 8641), Sall4
(1 µg ml −1 ) (Abcam, ab57577), Nanog (1:500) (Calbiochem, SC1000), Sox2 (1:1,000) (Santa Cruz, SC-17320), Tcfcp2l1 (1 µg ml −1 ) (R&D, AF5726), hCD4 (0.5 µl per 10 6 cells) (clone RPA-T4, eBioscience, 13-0049-80), β-catenin (1:1,000) (BD Biosciences, 610153).
Chimaeric mice. For the chimaera formation assay, 10-15 iPS cells (Agouti colour coat) were injected into 3.5 dpc blastocysts of C57BL/6-Albino mice (white coat colour). Chimaerism of the transplanted offspring was assessed by the presence of agouti coat colour derived from the iPS cells.
Whole-cell proteomic analysis. Sample preparation for mass spectrometry was performed essentially as described previously 65 . Cells were lysed in lysis buffer (6 M guanidinium chloride, 10 mM TCEP), incubated for 10 min at 95 • C and sonicated for 15 min using a Bioruptor. Proteins were alkylated with 40 mM 2-chloroacetamide, diluted tenfold with digestion buffer (20 mM Tris-HCl, pH 8.5 and 10% ACN) and digested with 1:50 (w/w) Lys-C (Wako) and 1:50 (w/w) trypsin (Promega) at 37 • C overnight. The resulting peptide mixture was acidified by addition of 1% TFA and desalted on StageTips with three layers of SDB-RPS. Peptides were separated on 50-cm columns of ReproSil-Pur C18-AQ 1.9 µm resin (Dr. Maisch GmbH) packed in-house. Liquid chromatography was performed on an EASY-nLC 1000 ultrahigh-pressure system coupled through a nanoelectrospray source to a Q-Exactive mass spectrometer (all from Thermo Fisher Scientific). Peptides were loaded in buffer A (0.1% formic acid) and separated applying a nonlinear gradient of 5-60% buffer B (0.1% formic acid, 80% acetonitrile) at a flow rate of 250 nl min −1 over 240 min. Data acquisition switched between a full scan and five data-dependent MS/MS scans. Multiple sequencing of peptides was minimized by excluding the selected peptide candidates for 45 s. For AP-MS experiments, a linear gradient of 5-30% buffer B was applied over 70 min, with dynamic exclusion set to 15 s.
ATAC-seq. ATAC-seq was performed as previously described 40 . A total of 100,000 cells were washed once with 100 µl PBS and resuspended in 50 µl lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.2% IGEPAL CA-630). The suspension of nuclei was then centrifuged for 10 min at 500g at 4 • C, followed by the addition of 50 µl transposition reaction mix (25 µl TD buffer, 2.5 µl Tn5 transposase and 22.5 µl nuclease-free H 2 O) and incubation at 37 • C for 45 min. DNA was isolated using the MinElute Kit (Qiagen). Library amplification was done by two sequential PCR reactions (8 and 5 cycles, respectively). After the first PCR reaction, the library was selected for fragments below 700 bp with AmpureXP beads followed by a second PCR reaction. Libraries were purified with Qiaquick PCR (Qiagen) and integrity checked on a Bioanalyser before sequencing.
Bioinformatic analyses. All sequencing data were mapped onto the mouse genome assembly mm10 (Ensembl GRCm38.78) using STAR (-outFilterMultimapNmax 1 -outFilterMismatchNmax 999 -outFilterMismatchNoverLmax 0.06; for RNA-seq: -sjdbOverhang 100 -outFilterType BySJout -alignSJoverhangMin 8 -alignSJDBoverhangMin 1 -alignIntronMin 20 -alignIntronMax 1000000 -alignMatesGapMax 1000000; for genomic sequencing: -alignIntronMax 1 -alignEndsType EndToEnd -alignMatesGapMax 2000) and analysed with R (3.1.0) using packages from the bioconductor suite (v3.0). For peak calling, regions overlapping the 'Encode blacklist' were removed. All clusterings were performed using the Rpackage Mfuzz (2.26.0). All GO enrichment analyses were performed using the Rpackage ReactomePA (1.10.1).
For RNA-seq, mapping was performed using Ensembl annotation (GRCm38.78). Genes expression quantification was performed using the Rpackage Rsubread (1.16.1). Sample scaling and statistical analysis were performed using the Rpackage DESeq2 (1.6.3) and vsd counts were used for further analysis. Genes changing significantly at any time point were identified using the nbinomLRT test (FDR < 0.01) and for >2-fold change between at least two time points (average of replicates, vsd values). Genes upregulated between two time points were selected using the nbinomWaldTest (FDR < 0.01) and for >1.5-fold change.
For ATAC-seq, duplicates reads were removed using Picard (http://picard. sourceforge.net) (MarkDuplicates, REMOVE_DUPLICATES=true). Bigwig tracks were made using DeepTools BamCoverage (1.5.9.1). Peak calling was performed using macs2 (2.1.0.20140616) (-f BAMPE -g mm -p 0.001 -nolambda). For quantitative analyses, peaks from all time points were merged as one set of nonoverlapping regions using Bedops. Reads were counted on merged regions for each time point, using the Rpackage csaw (1.0.7). Counts were scaled on genome-wide fragments using the Rpackage csaw (function WindowCounts on 10 kb windows), and size factors were calculated using DESeq2. Scaled counts were transformed to a log 2 scale (with pseudo-count of 1). Regions becoming more accessible in Bα cells were identified as showing a >1.5-fold increase after pulse and a difference of more than 10 fragments, and a difference of >2-fold changes and >40 fragments between any of the time points. Association of peaks with genes was performed with the Rpackage ChipPeakAnno, using Ensembl transcripts (GRCm38.78).
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Motif analyses were performed using RSAT. Repeats from the Ensembl annotation (GRCm38.75) were masked using bedtool maskfasta. Motif discovery was performed using peaks-motif and compared with the databases JASPAR (v.2015.03) and HOCOMOCO (v9). Motif enrichment in ATAC-seq clusters was performed with matrixQuality. We used as background a Markov model of order 1. The maximum-normalized-weight-difference score (MNWD) of matrix quality was used as enrichment score.
For the ChIP-seq, duplicate reads were removed using picard. Bigwig tracks were made using DeepTools BamCompare to subtract the input from the ChIP (-scaleFactorsMethod SES -ratio subtract -fragmentLength 200). H3K27ac peak calling was performed using macs2 on immunoprecipitation versus input (-broad -q 0.01, -broad-cutoff 0.01). Super-enhancers were called using ROSE (ref. 66) on H3K27ac data (-t 2500). Quantitative analyses were performed as for ATAC-seq. Average plots were obtained using DeepTools computeMatrix and profilers.
For proteomic, raw mass-spectrometry data were analysed with the MaxQuant workflow (1.5.1.6 and 1.5.3.29). Peak lists were searched against the Uniprot mouse FASTA database (2013_05) combined with 262 common contaminants by the integrated Andromeda search engine. FDR was set to 1% for both peptides (minimum length of 7 amino acids) and proteins. 'Match between runs' (MBR) with a maximum time difference of 0.7 min was enabled. Relative protein amounts were determined by the MaxLFQ algorithm, with a minimum ratio count of two peptides. Missing values were input from a normal distribution using the Perseus software package (width = 0.2, downshift = 1.8 s.d.).
For AP-MS, Student's t-test was applied for detection of differentially enriched proteins between triplicate immunoprecipitations of specific antibody and control IgG. For total protein analysis, proteins changing significantly at any time point were identified using an LRT test (FDR < 0.1) from the Rpackage msmsTests. Proteins changing between two time points were selected for 1.5>-fold change between each replicate (all four comparisons).
For the 4C analysis, the sequence of the reading primer was trimmed from the 5 of reads using the demultiplex.py script from the R package fourCseq (version 1.0.0, allowing 4 mismatches). Reads in which this sequence could not be found were discarded. Reads were mapped using STAR and processed using fourCseq to filter out reads not located at the end of a valid fragment and to count reads per fragment. Tracks of signal were made after smoothing the RPKM counts per fragment with a running mean over five fragments.
Independent component analysis (ICA) and canonical correlation analysis (CCA) were performed on gene expression data using the R packages fastICA and CCA, respectively.
All codes for bioinformatic analysis are available on request. The RNA-seq, ChIP-seq and ATAC-seq data obtained for B cells, Bα cells, day 1 cells, day 2 cells and ESCs described in this paper have been deposited in GEO under the number GSE71218. Proteomic data have been deposited in proteome Xchange under the identifier PXD002769.
Statistics and reproducibility. Western blot, immunoprecipitation, ChIP, qRT-PCR, immunofluorescence, immunoprecipitation mass spectrometry, alkaline phosphate and FACS data presented are representative of at least three independent experiments that yielded similar results; microarray, RNA-seq and proteomic data were obtained from two independent experiments that yielded similar results. Statistical analyses were performed using Prism software (GraphPad). No statistical method was used to predetermine sample size and the experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Prdm9, Pou5f2, Arid3a, Klf7, Pou2f2
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